#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	12788	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2172	583.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1664	1664	T	674	T	627	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	12788	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2172	583.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1398	1398	C	788	C	739	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	12788	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2172	583.3	0	HET	.	.	.	C790T	.	790	790	C	1004	1004	C	742	C,T	548,155	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	12788	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2172	583.3	0	HET	.	.	.	C712T	.	712	712	C	926	926	C	714	C,T	527,158	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23810	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3632	653.9	0	.	n	.	0	C543T	SNP	543	543	C	924	924	T	815	T,C,G	758,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23810	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3632	653.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1718	1718	A	801	A	755	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23810	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3632	653.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2352	2352	C	733	C	680	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23810	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3632	653.9	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2978	2978	T	695	T,C	659,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23810	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3632	653.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2426	2426	A	783	A	735	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	1942	folP	855	855	99.88	folP.l6.c30.ctg.1	1517	127.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1030	1032	AGC	193;191;191	A;G;C	187;184;182	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5418	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3446	156.9	0	.	p	.	0	V290I	NONSYN	868	870	GTT	1186	1188	ATT	146;146;149	A;T;T	142;141;144	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5418	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3446	156.9	1	SNP	p	S91F	0	.	.	271	273	TCC	589	591	TCC	197;198;201	T;C,T;C	192;192,1;196	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5418	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3446	156.9	1	SNP	p	D95G	0	.	.	283	285	GAC	601	603	GAC	205;202;206	G;A,G;C	198;194,1;197	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5418	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3446	156.9	1	SNP	p	D95N	0	.	.	283	285	GAC	601	603	GAC	205;202;206	G;A,G;C	198;194,1;197	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	1616	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1340	120.3	1	SNP	p	G45D	1	.	.	133	135	GAC	483	485	GAC	223;221;222	G;A;C,A	204;207;205,1	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	862	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1038	82.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4778	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2981	159.8	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1645	1647	GCA	187;190;195	G;C;A	169;171;177	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4778	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2981	159.8	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2128	2130	ATT	211;208;209	A;T;T	193;191;195	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4778	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2981	159.8	1	SNP	p	D86N	0	.	.	256	258	GAC	598	600	GAC	195;194;195	G;A;C	188;185;191	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4778	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2981	159.8	1	SNP	p	S87I	0	.	.	259	261	AGT	601	603	AGT	195;192;193	A;G;T	191;189;189	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4778	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2981	159.8	1	SNP	p	S87W	0	.	.	259	261	AGT	601	603	AGT	195;192;193	A;G;T	191;189;189	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4778	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2981	159.8	1	SNP	p	S87R	0	.	.	259	261	AGT	601	603	AGT	195;192;193	A;G;T	191;189;189	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4778	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2981	159.8	1	SNP	p	S88P	0	.	.	262	264	TCC	604	606	TCC	195;199;199	T;C;C	189;192;191	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4102	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2547	160.1	0	.	p	.	0	H611N	NONSYN	1831	1833	CAC	2053	2055	AAC	195;192;192	A;A;C	176;168;175	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4102	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2547	160.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1450	1452	GGC	194;192;191	G;G;C	179;177;175	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	0	.	p	.	0	M35I	NONSYN	103	105	ATG	417	419	ATA	166;165;168	A;T;A	156;154;157	.	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	0	.	p	.	0	C41G	NONSYN	121	123	TGT	435	437	GGT	174;173;170	G;G;T	163;162;159	.	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	0	.	p	.	0	A70T	NONSYN	208	210	GCA	522	524	ACA	184;182;179	A;C;A	175;173;171	.	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	0	.	p	.	0	D101E	NONSYN	301	303	GAT	615	617	GAG	172;173;175	G;A;G	167;165;167	.	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	0	.	p	.	0	Y201H	NONSYN	601	603	TAT	915	917	CAT	204;206;205	C;A;T	196;198;198	.	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	0	.	p	.	0	Q230K	NONSYN	688	690	CAA	1002	1004	AAA	184;182;183	A,G;A;A	166,1;170;173	.	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	0	.	p	.	0	L447V	NONSYN	1339	1341	CTC	1653	1655	GTC	197;199;200	G;T;C	189;192;193	.	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	0	.	p	.	0	V515I	NONSYN	1543	1545	GTC	1857	1859	ATC	183;184;184	A;T,A;C	172;168,1;175	.	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1245	1247	GCA	180;179;179	G;C;A	162;158;164	penA.0.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1248	1250	ATC	177;177;180	A;T;C	163;164;167	penA.0.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1260	1262	GTG	176;177;178	G;T;G	162;163;164	penA.0.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1260	1262	GTG	176;177;178	G;T;G	162;163;164	penA.0.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1761	1763	ACC	179;180;179	A;C;C	166;169;170	penA.0.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1815	1817	GCG	178;178;177	G;C;G	146;134;142	penA.0.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1815	1817	GCG	178;178;177	G;C;G	146;134;142	penA.0.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	1	SNP	p	G545S	0	.	.	1633	1635	GGC	1947	1949	GGC	156;154;153	G;G;C	147;145;145	penA.0.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3444	penA	1746	1746	98.17	penA.l15.c4.ctg.1	2322	147.4	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1965	1967	CCG	126;125;124	C,CGG;C;G	98,1;99;97	penA.0.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5114	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3123	163.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2378	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1763	133.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	571	571	C	182	C	169	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2480	porB1b	1035	1035	97.69	porB1b.l15.c4.ctg.1	1490	164.0	0	.	p	.	0	G129_K130del	DEL	385	385	G	650	650	G	219	G,T	203,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2480	porB1b	1035	1035	97.69	porB1b.l15.c4.ctg.1	1490	164.0	0	.	p	.	0	R143G	NONSYN	427	429	AGA	680	682	GGA	221;220;219	G;G,A;A	206;205,1;198	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2480	porB1b	1035	1035	97.69	porB1b.l15.c4.ctg.1	1490	164.0	0	.	p	.	0	.	INDELS	629	630	AA	883	885	TAG	201;201;199	T;A;G	192;193;189	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2480	porB1b	1035	1035	97.69	porB1b.l15.c4.ctg.1	1490	164.0	0	.	p	.	0	.	MULTIPLE	631	633	TAC	887	890	CAAT	198;201;202;202	C;A;A;T	187;190;193;190	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2480	porB1b	1035	1035	97.69	porB1b.l15.c4.ctg.1	1490	164.0	0	.	p	.	0	N212fs	FSHIFT	634	634	A	892	892	T	204	T	190	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2480	porB1b	1035	1035	97.69	porB1b.l15.c4.ctg.1	1490	164.0	1	SNP	p	G120K	0	.	.	358	360	GGT	623	625	GGT	213;211;210	G;G;T	200;194;195	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2480	porB1b	1035	1035	97.69	porB1b.l15.c4.ctg.1	1490	164.0	1	SNP	p	A121D	0	.	.	361	363	GCC	626	628	GCC	210;212;212	G;C;C	194;197;198	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2480	porB1b	1035	1035	97.69	porB1b.l15.c4.ctg.1	1490	164.0	1	SNP	p	A121N	0	.	.	361	363	GCC	626	628	GCC	210;212;212	G;C;C	194;197;198	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	8630	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	4924	174.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2044	2046	CAT	188;187;185	C;A;T,C	178;179;175,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1026	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1090	93.8	1	SNP	p	V57M	0	.	.	169	171	GTG	580	582	GTG	221;220;219	G;T;G	213;209;211	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
